• Home
  • About Us
  • Blog

Pulmonary Hypertension RN

  • What is Pulmonary Hypertension?
    • What is Pulmonary Hypertension?
    • Pulmonary Hypertension Symptoms
    • Types of Pulmonary Hypertension
    • Causes of Pulmonary Hypertension
    • PH vs. PAH
    • Diastolic Heart Failure vs. PAH
    • WHO Group 3 Pulmonary Hypertension, IPF & COPD
    • Pulmonary Veno-Occlusive Disease
    • Hereditary Hemorrhagic Telangiectasia (HHT)
      • Hereditary Hemorrhagic Telangiectasia (HHT) Treatment
    • Functional Classification of Pulmonary Hypertension
    • Congenital Heart Disease
      • Eisenmenger’s Syndrome
      • Update on Management of PAH-CHD
      • Congenital Heart Disease & Sleep Apnea
      • Complex Congenital Heart Disease
      • Atrial Septal Defect and Pulmonary Arterial Hypertension
    • Pediatric Pulmonary Arterial Hypertension
    • Sickle Cell and Pulmonary Hypertension
    • Stimulant Associated Pulmonary Arterial Hypertension
    • Porto-Pulmonary Syndrome
    • Research, Life Expectancy & Prognosis for PH
  • Diagnosing & Monitoring PAH
    • Pulmonary Arterial Hypertension Diagnosis
    • How Am I Doing? Assessing Your PAH.
    • Blood Tests
    • Cardiopulmonary Exercise Test (CPET)
    • CT (Computed Tomography) Scan
    • Echocardiogram: An Overview
    • Echocardiogram: A Detailed Look
    • Pulmonary Function Tests (PFTs)
    • Right Heart Catheterization
    • Six Minute Walk
    • Ventilation Perfusion Scan (VQ Scan)
    • CTEPH
      • CTEPH: WHO Group 4 Pulmonary Hypertension
      • PTE (Pulmonary Thromboendarterectomy) Surgery
      • Adempas used to Treat PAH and CTEPH
  • PAH Treatment
    • Pulmonary Hypertension Centers
    • Pulmonary Hypertension Treatments
    • Continuously Infused Therapies Used to Treat PH
    • Prostanoids for Treatment of PH
    • Adcirca and Revatio Used to Treat Pulmonary Arterial Hypertension (PAH)
    • Adempas used to Treat PAH and CTEPH
    • Tracleer, Letairis, and Opsumit Treatments
    • Oxygen Therapy for Pulmonary Hypertension
    • Salt and Water Restrictions
    • Exercise & PAH
    • Diuretics
    • Blood Thinners
    • Getting the Most Out of PAH Therapy
      • Letairis
      • Opsumit
      • Sildenafil (Revatio)
  • Research
  • FAQ’s
    • Implanted Remodulin Pump, Right Heart Catheterization, PAH & Pregnancy
    • Oral Treatments, Care Centers & Hole in Heart
    • FAQ’s: Altitude, Cold & Allergy Medications
    • FAQ’s: Psoriasis, Idiopathic PAH, Contraceptives & PAH
    • FAQ’s: Causes of Pulmonary Hypertension, Symptom Frequency & Care Centers
    • FAQ: PAH Experts, Pregnancy, Mild PAH & Vacationing
    • FAQ’s: CTEPH, Blood Clots, Corrective Surgery & PAH Care Centers
    • FAQ’s: VQ Scans & PAH Curable?
    • FAQ’s: Mild Pulmonary Hypertension?
    • FAQ’s: Boating, Swimming & Eating with PAH
    • FAQ’s: Borderline Pulmonary Hypertension, Hand Swelling, Children with PAH, Costs

Hereditary Hemorrhagic Telangiectasia (HHT)

December 15, 2017 By Dr. Jeremy Feldman

blood vesselsDisease Overview

HHT is a rare disease that leads to abnormal blood vessel growth throughout the body.  This commonly leads to frequent nose bleeds (epistaxis), gastro-intestinal bleeding and anemia.  The more serious manifestations include abnormal blood vessels in the lungs, brain and liver.  These abnormal blood vessels can lead to infections in the brain, bleeding in the brain, liver failure and pulmonary arterial hypertension.

Who gets HHT?

HHT is a genetic disorder that is inherited from your parent.  It is autosomal dominant.  This means that if one of your parents has the disease there is a 50% chance that each child will develop the disease.  About 1 in 5000 to 8000 people are affected by the disease.  This means that there are about 50,000-100,000 affected people in the United States.  All races and ethnicities are affected by HHT.

What causes HHT?

There are three common genes that have been identified that lead to HHT.  Mutations in Endoglin lead to HHT1.  Mutations in ALK-1 lead to HHT2.  Mutations in SMAD4 lead to juvenile polyposis-HHT (JPHT) overlap syndrome.  Although earlier work suggested that HHT1 and HHT2 patients had different disease manifestations, recent work suggests that this may not be the case.  The mutations in the genes that lead to HHT cause abnormal signaling by affecting TGF-Beta proteins.

Clinical Manifestations

Telangiectasias is the most common manifestation seen in all patients with HHT.  These are tiny red dots or lines that most commonly develop on the lips, face, chest, fingertips.  These are small abnormal blood vessels that are just under the skin or mucous membranes (mouth, nose or gastro-intestinal tract).  These abnormal blood vessels are prone to bleeding.  This leads to the most common symptom in HHT—nose bleeds.  Almost all patients with HHT experience nose bleeds starting at an early age.  It is important to remember that nose bleeds are common in the absence of HHT so the vast majority of people that have nose bleeds do not have HHT.

Arteriovenous malformations (AVMs) are larger blood vessels that form abnormally and connect the artery to a vein.  These range from very small in size to very large.  They commonly develop in the gastrointestinal tract, lungs, liver and brain.  Although these abnormal blood vessels are less common than telangiectasias, they can cause life threatening problems.

  1. Pulmonary AVMs can lead to stroke and brain abscess when particulates or bacteria travel to the brain bypassing the filtering system in the lungs.  If pulmonary AVMs rupture (pop) this can lead to life-threatening bleeding.  Low oxygen levels are commonly associated with these abnormal blood vessels in the lungs.  As blood bypasses the proper circulation, blood without oxygen is mixed with oxygenated blood (shunting).  The net result is lower oxygen levels.  Some patients will notice shortness of breath.  In large pulmonary AVMs, the right side of the heart has to work extra hard and this may lead to right heart failure.
  2. Gastrointestinal (Bowel) AVMs may bleed.  This is recognized by passing large amounts of red, maroon or dark blood in your stool.
  3. Brain AVMs represent a particular challenge.  These abnormal vessels are prone to bleeding.
  4. Liver AVMs can lead to slowly progressive confusion and eventually liver failure.

Aneurysms in blood vessels of the brain may also be seen in about 10% of HHT patients.  These abnormal outpouchings of the vessels are more likely to bleed leading to a type of stroke called subarachnoid hemorrhage.

Iron deficiency anemia is very common in HHT patients.

Pulmonary Arterial Hypertension with HHT

Pulmonary arterial hypertension develops in about 10-15% of patients with HHT.  These patients will notice increasing shortness of breath as the most common symptom.  The disease is indistinguishable from idiopathic pulmonary arterial hypertension in symptoms.

Migraine headache and blood clots are more common in patients with HHT.

How do we make the diagnosis of HHT?

There was an international meeting years ago in Curacao that resulted in an agreement on how we make the diagnosis of HHT.  Four criteria were identified including frequent nose bleeds, multiple telangiectasias, abnormal blood vessels in the lungs/liver/brain/GI tract, and a family member with HHT.  Each of these is given one point.

  • Definite disease:  at least 3 of the 4 criteria
  • Suspected disease:  2 criteria
  • Unlikely:  1 criteria

Genetic testing is available but not required to make the diagnosis.  Identifying a mutation in the genes that cause HHT confirms the diagnosis.  However, many patients will have mutations that are not able to be identified at this time.

Arteriovenous Malformations (AVMs) are identified by CT scanning or angiography of the lungs, abdomen, or brain.

Pulmonary hypertension is often suggested by an abnormal echocardiogram and then confirmed with right heart catheterization.

For information about the treatment of HHT click here.

Filed Under: Pulmonary Hypertension Diagnosis

PAH Life Expectancy

PAH Research

Research, Life Expectancy & Prognosis for PH

Major Developments in Pulmonary Hypertension Affecting Prognosis 1.     Approval of

Where to Get Treatment?

CCCs for PAH

Pulmonary Hypertension Centers

Where to get treatment for pulmonary hypertension? Pulmonary arterial hypertension is a

Popular Posts

Update on PAH Treatments

FDA Approves Changes to the Letairis REMS Program

By Dr. Jeremy Feldman

In August 2013 the FDA (Food and Drug Administration) approved changes to the Letairis Risk Evaluation and Mitigation

pulmonary hypertension research laboratory

Serotonin and Pulmonary Arterial Hypertension

By Dr. Jeremy Feldman

Serotonin is an important molecule in our bodies.  It works in our brain to regulate mood, appetite, sleep,

good news in pah

 

Disclaimer

Recent Blog Posts

  • In Memoriam:  Greg Ahearn, MD June 16, 2024
  • Sotatercept (Winrevair) Approved! June 1, 2024
  • Disappointing News for Rodatristat Ethyl October 11, 2023

Categories

Archives